(Q44117835)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12200667%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

title

Effects of imatinib on bone marrow engraftment in syngeneic mice (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12200667%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12200667%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

author name string

Hoepfl J

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12200667%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Grundler R

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12200667%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Götze KS

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12200667%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Peschel C

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12200667%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Duyster J

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12200667%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

publication date

1 September 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12200667%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12200667%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12200667%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12200667%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

page(s)

1584-1588

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12200667%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.leu.2402679

12 November 2019

exact match

0 references

cites work

The biology of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402679

7 January 2021

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402679

7 January 2021

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402679

7 January 2021

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402679

7 January 2021

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402679

7 January 2021

Implications of imatinib mesylate for hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402679

7 January 2021

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402679

7 January 2021

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402679

7 January 2021

Roots of clinical resistance to STI-571 cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402679

7 January 2021

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402679

7 January 2021

Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402679

7 January 2021

Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402679

7 January 2021

Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402679

7 January 2021

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402679

7 January 2021

Molecular cloning of mast cell growth factor, a hematopoietin that is active in both membrane bound and soluble forms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402679

7 January 2021

Expression of c-kit gene products in known cellular targets of W mutations in normal and W mutant mice--evidence for an impaired c-kit kinase in mutant mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402679

7 January 2021

Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402679

7 January 2021

Purification and characterization of mouse hematopoietic stem cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402679

7 January 2021

Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402679

7 January 2021

Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402679

7 January 2021

Translating stem and progenitor cell biology to the clinic: barriers and opportunities

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402679

7 January 2021

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402679

7 January 2021